Intelligence · Clinical pipeline
Infectious disease · Phase I
Infectious disease programs at Phase I — ClinicalTrials.gov pipeline intelligence.
Quick answer
Infectious disease Phase I programs: NovaPharmaNews indexes 237 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.
Top sponsors
- United Therapeutics Europe 23 programs
- ENANTA PHARMACEUTICALS 14 programs
- Vertex Pharmaceuticals (Australia) 11 programs
- BRIGHT MINDS BIOSCIENCES 10 programs
- Chinese Academy of 10 programs
- ASSEMBLY BIOSCIENCES 9 programs
- Aligos Therapeutics 8 programs
- Anaxis Pharma 8 programs
- Sunshine Guojian Pharmaceutical 8 programs
- INOVIO Pharmaceuticals 7 programs
- MSD Merck Sharp 6 programs
- Sinovac Research and 6 programs
Pipeline programs
-
(+)-SJ000557733
CNS Pharmaceuticals
Plasmodium Falciparum Malaria
1 trial -
01-AMO-CLA-BIO-25
Zaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A.
infections
1 trial -
091
United Therapeutics Europe Ltd
HIV Infections
1 trial -
11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
HPV Infection
1 trial -
1524-0001
Boehringer Ingelheim
Metabolic Dysfunction-associated Steatohepatitis
1 trial -
221794
ViiV Healthcare Pty Ltd
HIV Infections
1 trial -
222110
GlaxoSmithKline
Hepatitis B, Chronic
1 trial -
222261
GlaxoSmithKline
Respiratory Syncytial Virus Infections
1 trial -
22265
Bayer AG
Coagulopathy, Sepsis
1 trial -
222778
GlaxoSmithKline
Urinary Tract Infections
1 trial -
22534
Bayer AG
Onchocerciasis (river blindness): is an infectious disease caused by Onchocerca volvulus, a parasitic nematode worm. The disease is contracted through the bite of an infected blackfly of the genus Simulium, which transmits third-stage infective larvae. An estimated 18 million people suffer from onchocerciasis, with 99% cases in 31 African countries, and 187 million people at risk Onchocercal dermatitis is the most common symptom of the disease, but severe visual impairment and blindness are the most severe complication, and onchocerciasis is the world’s second-leading infectious cause of blindness. Programs for the treatment and control of onchocerciasis through mass drug administration of ivermectin have been in place for over 20 years. However, they require patients to be given treatment (ivermectin) at regular intervals for the life of the adult worm (up to 15 years), making implementation extremely difficult in endemic countries. Emodepside is a registered drug for animal health, marketed by Bayer Animal Health GmbH under the name of Profender® (in combination with praziquantel) or Procox® (in combination with toltrazuril). It is a cyclooctadepsipeptide anthelmintic drug., Soil-transmitted helminth infection: Soil-transmitted helminthiasis is caused by one of the three soil-transmitted helminths (STH), Ascaris lumbricoides, Trichuris trichiura and hookworm (Ancylostoma duodenale and Necator americanus). Currently, STH still infects about 1.5 billion people worldwide, mostly in tropical and subtropical regions. Emodepside is a registered drug for animal health, marketed by Bayer Animal Health GmbH under the name of Profender® (in combination with praziquantel) or Procox® (in combination with toltrazuril). It is a cyclooctadepsipeptide anthelmintic drug.
1 trial -
22537
Bayer AG
Soil-transmitted helminth infection, Onchocerciasis (river blindness)
1 trial -
480 mg Piperaquine phosphate
CNS Pharmaceuticals
Malaria
1 trial -
9vHPV Vaccine plus BCG Vaccine Mix for percutaneous use
Lxo Ireland Designated Activity Company
HPV Infection
1 trial -
A clinical study of MK-1289 in healthy adult men (MK-1289-001)
Merck Sharp and Dohme
COVID-19 Infection
1 trial -
A clinical study of MK-3508 in healthy people (MK-3508-006)
Merck Sharp and Dohme
Respiratory syncytial virus infection
1 trial -
A clinical study of MK-4646 in healthy people (MK-4646-002)
Merck Sharp and Dohme
HIV infection
1 trial -
A clinical study of MK-4646 in people with HIV (MK-4646-003)
Merck Sharp and Dohme
HIV infection
1 trial -
A single-dose for infection
Zaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A.
infection
1 trial -
A single-dose for infections
Zaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A.
infections
1 trial -
A study to compare two different aramchol formulations in healthy volunteers.
Galmed Pharmaceuticals
Nonalcoholic fatty liver disease, Nonalcoholic steatohepatitis, Primary sclerosing cholangitis
1 trial -
AB-101
Arbutus Biopharma Corp
Chronic Hepatitis b
1 trial -
AB-101-001
Arbutus Biopharma Corp
Chronic hepatitis B virus Infection
1 trial -
AB-836
Arbutus Biopharma Corp
Chronic Hepatitis
1 trial -
ABI-4334
ASSEMBLY BIOSCIENCES, INC.
Chronic Hepatitis B
1 trial -
ABI-4334 Tablet
ASSEMBLY BIOSCIENCES, INC.
Chronic Hepatitis B
1 trial -
ABI-4334-102
ASSEMBLY BIOSCIENCES, INC.
chronic hepatitis B virus infection (cHBV)
1 trial -
ABI-6250
ASSEMBLY BIOSCIENCES, INC.
Hepatitis Delta Virus
1 trial -
ABI-H2158
ASSEMBLY BIOSCIENCES, INC.
Chronic Hepatitis B
3 trials -
ABI-H2158 Reference Formulation
ASSEMBLY BIOSCIENCES, INC.
Chronic Hepatitis B
1 trial -
ABI-H3733
ASSEMBLY BIOSCIENCES, INC.
Chronic Hepatitis B
1 trial -
ABI-H3733 Liquid Oral Dosage Form
ASSEMBLY BIOSCIENCES, INC.
Chronic Hepatitis B
1 trial -
ALG-000184
Aligos Therapeutics
Chronic Hepatitis B
1 trial -
ALG-010133
Aligos Therapeutics
Chronic Hepatitis B
1 trial -
ALG-020572
Aligos Therapeutics
Chronic Hepatitis B
1 trial -
ALG-055009
Aligos Therapeutics
NASH - Nonalcoholic Steatohepatitis
1 trial -
ALG-097558
Aligos Therapeutics
COVID-19
3 trials -
ALG-125755
Aligos Therapeutics
Chronic Hepatitis B
1 trial -
ALN-HBV
Alnylam Netherlands B.V.
Hepatitis B
1 trial -
ALN-HSD
Alnylam Netherlands B.V.
Nonalcoholic Steatohepatitis
1 trial -
ALS-002158
Vertex Pharmaceuticals (Australia) Pty.
Hepatitis C, Chronic
1 trial -
ALS-002200
Vertex Pharmaceuticals (Australia) Pty.
Hepatitis C, Chronic
1 trial -
APC148-001
Lacuna Pharma Pty Ltd
Urinary tract infections (UTIs)/complicated UTI (cUTI)
1 trial -
APR002
BRIGHT MINDS BIOSCIENCES INC.
COVID-19
1 trial -
ARC-521 Injection
Arrowhead Pharmaceuticals Ireland Limited
Hepatitis B
1 trial -
ARS-1 with URTI
Ars Pharmaceuticals Irl Limited
Upper Respiratory Tract Infection
1 trial -
AT-527
Atea Pharmaceuticals
Chronic Hepatitis C
1 trial -
Active Delta-9-THC
BRIGHT MINDS BIOSCIENCES INC.
HIV Infections
1 trial
Frequently asked questions
How many infectious disease Phase I programs exist?
237 programs match both the therapeutic area and stage filters in our published index.